Lianhuan Pharmaceutical announced that the company obtained the “Drug Supplement Application Approval Notice” for vigliptin tablets and became the marketing license holder for the drug. The drug's approval number remained the same. The production site, prescriptions, production process, quality standards, etc. were consistent with the original drug, and it can be marketed and sold after passing compliance checks with drug production quality management standards and meeting release requirements. Vildagliptin tablets are mainly used to treat type 2 diabetes. Domestic medical institutions had sales of about 117 million yuan in 2025, and sales of 48 million yuan in the first two quarters of 2026. The company has invested a total of about 1.88 million yuan in this drug. As of the disclosure date, the company and its subsidiaries have obtained a total of 13 production approvals in 2026. The matter is not expected to have a significant impact on the company's recent business performance, and there is uncertainty about drug sales.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.